Navigation Links
Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
Date:6/12/2012

LEXINGTON, Mass., June 12, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs, announced today that Michael D. Rivard has joined the company as Vice President, Corporate Development.

Mr. Rivard has over 20 years of experience in the biotechnology industry and has held senior management positions in corporate development at ArQule, Inc., Synta Pharmaceuticals Corp., Galenea Corp., and VaxDesign Corporation.  Mr. Rivard also served as Associate Counsel (Intellectual Property) at the University of Massachusetts and as an Associate Attorney at the law firm of Palmer & Dodge (now Edwards Wildman Palmer LLP).  Mr. Rivard earned a Juris Doctor degree from the UCLA School of Law and a BA degree in biochemistry from Bowdoin College.

"I am thrilled to join this exciting company," said Mr. Rivard.  "The AVX Oral Antibody™ technology makes the gastrointestinal (GI) tract accessible to potent and safe antibody therapy.  Potential applications for our antibodies include inflammatory bowel disease (IBD), oral mucositis, GI acute radiation syndrome, celiac disease, diabetes, and any other disease which involves an antigen, soluble protein, or receptor in the GI tract or oral cavity.  The breadth of the platform offers many opportunities to work with collaborators in the pharmaceutical industry as we develop our lead product for IBD."

Barbara S. Fox, CEO of Avaxia, added, "Mike brings to Avaxia a unique mix of knowledge and experience in corporate development, intellectual property, and corporate law, as well as a scientific background.  We are confident that Mike will lead us successfully in achieving our goals of partnering our AVX-470 oral anti-TNF antibody and finding collaborators who share our vision of developing oral antibodies for other exciting targets in the GI tract."

About Avaxia Biologics, Inc.: Avaxia Biologics is developing orally administered antibody therapeutics that act locally within the gastrointestinal (GI) tract.  Antibodies are widely used as therapeutics and have nearly $50 billion in annual sales worldwide.  Ordinary antibodies are not administered orally because they are destroyed in the GI tract.  In contrast, Avaxia has developed proprietary antibodies that are stable in the GI tract.  AVX Oral Antibodies™ make disease targets in the GI tract readily accessible to antibody therapeutics.  Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
2. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
3. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... , ... October 11, 2019 , ... Based on data ... a 9 percent increase in deceased organ donors over 2018. Through August 31, 7,786 ... Transplantation Network (OPTN) national database . At this pace, the Association of Organ ...
(Date:10/10/2019)... ... October 10, 2019 , ... ... Cocktail Reception on Thursday, September 26, at the Westchester Country Club in Rye. ... unwavering support of the organization and its mission. , “In Celebration” featured live ...
(Date:10/8/2019)... ... , ... “When Seconds Count: Reports From an Emergency Medical Helicopter Pilot”: a ... through telling the real stories of the EMS flight crew. “When Seconds Count: Reports ... Humphrey, an EMS helicopter pilot. He has been a pilot in the HEMS industry ...
Breaking Medicine Technology:
(Date:10/8/2019)... AVON, Conn. (PRWEB) , ... October 08, 2019 ... ... fertility centers, recently acquired a majority interest in Advanced Fertility Care (AFC), an ... entities are joining forces to expand the availability of RE services to expectant ...
(Date:10/8/2019)... ... October 08, 2019 , ... PotentiaMetrics, an Austin, TX ... as Chief Medical Officer. Dr. Henderson will be responsible for the development and ... previously served as Chair of both the Informatics Governance and the Inpatient Clinical ...
(Date:10/8/2019)... ... October 08, 2019 , ... The University ... a Digital Health Awards 1st Round (Top Ten) Finalist in its Best Cardiovascular ... select companies that promote faster, better, more cost-effective healthcare by improving outcomes such ...
(Date:10/8/2019)... ... October 08, 2019 , ... Join ... PhD, D(ABMM), and Infectious Disease Physician at Loyola University Medical Center, Fritzie Albarillo, ... 1pm EDT. The speakers will discuss the benefits and challenges with implementing a ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... released the findings of a new study showing that Care4U™ 2’-FL, a DuPont ... to galacto-oligosaccharides (GOS) and lactose. The effects elicited to microbiota and metabolite composition ...
Breaking Medicine News(10 mins):